Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,876
edits
Changes
HAEM4:Monoclonal Immunoglobulin Deposition Diseases (view source)
Revision as of 16:34, 4 December 2023
, 16:34, 4 December 2023no edit summary
==General Disease Overview / Description of Cancer Category==
==General Disease Overview / Description of Cancer Category==
*The major classification group of Monoclonal Immunoglobulin Deposition Diseases, as described in the revised 4th edition of the WHO, includes the categories: [[Primary Amyloidosis]] and [[Light Chain and Heavy Chain Deposition Disease]]
*The major classification group of Monoclonal Immunoglobulin Deposition Diseases, as described in the revised 4th edition of the WHO, includes the categories: [[HAEM5:Immunoglobulin-related (AL) amyloidosis]] and [[HAEM5:Monoclonal immunoglobulin deposition disease]]
*The monoclonal immunoglobulin (Ig) deposition diseases are closely related disorders characterized by deposition of aberrant Ig (mostly light chain and rarely heavy chain) in various tissues, leading to organ dysfunction<ref>McKenna RW, et al., (2017). Plasma cell neoplasms: Monoclonal immunoglobulin deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p254-256.</ref>
*The monoclonal immunoglobulin (Ig) deposition diseases are closely related disorders characterized by deposition of aberrant Ig (mostly light chain and rarely heavy chain) in various tissues, leading to organ dysfunction<ref>McKenna RW, et al., (2017). Plasma cell neoplasms: Monoclonal immunoglobulin deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p254-256.</ref>
*Underlying disorders are [[Plasma Cell Neoplasms|plasma cell neoplasms]] or rarely lymphoplasmacytic neoplasm
*Underlying disorders are [[HAEM4:Plasma Cell Neoplasms|plasma cell neoplasms]] or rarely lymphoplasmacytic neoplasm
*Many patients at diagnosis have not developed overt myeloma or lymphoma
*Many patients at diagnosis have not developed overt myeloma or lymphoma
*Even with low clonal neoplastic burden, systemic Ig deposition often results in aggressive disease progression and organ failure if untreated
*Even with low clonal neoplastic burden, systemic Ig deposition often results in aggressive disease progression and organ failure if untreated
*While secreted monoclonal Ig products are soluble in most patients, some are amyloidogenic, and (more rarely) some are prone to form non-amyloid deposits
*While secreted monoclonal Ig products are soluble in most patients, some are amyloidogenic, and (more rarely) some are prone to form non-amyloid deposits
*There are two major types of monoclonal Ig deposition diseases: [[Primary Amyloidosis|primary amyloidosis]], or Ig light chain (AL) amyloidosis; and [[Light Chain and Heavy Chain Deposition Disease|light chain and heavy chain disposition diseases]]
*There are two major types of monoclonal Ig deposition diseases: [[HAEM5:Immunoglobulin-related (AL) amyloidosis|primary amyloidosis]], or Ig light chain (AL) amyloidosis; and [[HAEM5:Monoclonal immunoglobulin deposition disease|light chain and heavy chain disposition diseases]]
*Ig Heavy chain (AH) amyloidosis<ref>{{Cite journal|last=Eulitz|first=M.|last2=Weiss|first2=D. T.|last3=Solomon|first3=A.|date=1990-09|title=Immunoglobulin heavy-chain-associated amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/2118650|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=87|issue=17|pages=6542–6546|doi=10.1073/pnas.87.17.6542|issn=0027-8424|pmc=PMC54572|pmid=2118650}}</ref><ref>{{Cite journal|last=Solomon|first=A.|last2=Weiss|first2=D. T.|last3=Murphy|first3=C.|date=1994-02|title=Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/8141123|journal=American Journal of Hematology|volume=45|issue=2|pages=171–176|doi=10.1002/ajh.2830450214|issn=0361-8609|pmid=8141123}}</ref><ref>{{Cite journal|last=Miyazaki|first=Daigo|last2=Yazaki|first2=Masahide|last3=Gono|first3=Takahisa|last4=Kametani|first4=Fuyuki|last5=Tsuchiya|first5=Ayako|last6=Matsuda|first6=Masayuki|last7=Takenaka|first7=Yoshiaki|last8=Hosh|first8=Yoshinobu|last9=Ikeda|first9=Shu-ichi|date=2008-06|title=AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report|url=https://pubmed.ncbi.nlm.nih.gov/18484339|journal=Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis|volume=15|issue=2|pages=125–128|doi=10.1080/13506120802006229|issn=1744-2818|pmid=18484339}}</ref> and heavy-and-light-chain (AH/AL) amyloidosis are two rare forms of monoclonal Ig-related amyloidosis<ref>{{Cite journal|last=Nasr|first=Samih H.|last2=Said|first2=Samar M.|last3=Valeri|first3=Anthony M.|last4=Sethi|first4=Sanjeev|last5=Fidler|first5=Mary E.|last6=Cornell|first6=Lynn D.|last7=Gertz|first7=Morie A.|last8=Dispenzieri|first8=Angela|last9=Buadi|first9=Francis K.|date=2013-03|title=The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/23302715|journal=Kidney International|volume=83|issue=3|pages=463–470|doi=10.1038/ki.2012.414|issn=1523-1755|pmid=23302715}}</ref><ref>{{Cite journal|last=Chaulagain|first=Chakra P.|last2=Herlitz|first2=Leal C.|last3=Fu|first3=Julie|last4=Bilani|first4=Nadeem|last5=Lucitt|first5=Camerun|last6=Comenzo|first6=Raymond L.|date=2020-11|title=How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/32703752|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=11|pages=e826–e831|doi=10.1016/j.clml.2020.06.017|issn=2152-2669|pmid=32703752}}</ref>
*Ig Heavy chain (AH) amyloidosis<ref>{{Cite journal|last=Eulitz|first=M.|last2=Weiss|first2=D. T.|last3=Solomon|first3=A.|date=1990-09|title=Immunoglobulin heavy-chain-associated amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/2118650|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=87|issue=17|pages=6542–6546|doi=10.1073/pnas.87.17.6542|issn=0027-8424|pmc=PMC54572|pmid=2118650}}</ref><ref>{{Cite journal|last=Solomon|first=A.|last2=Weiss|first2=D. T.|last3=Murphy|first3=C.|date=1994-02|title=Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/8141123|journal=American Journal of Hematology|volume=45|issue=2|pages=171–176|doi=10.1002/ajh.2830450214|issn=0361-8609|pmid=8141123}}</ref><ref>{{Cite journal|last=Miyazaki|first=Daigo|last2=Yazaki|first2=Masahide|last3=Gono|first3=Takahisa|last4=Kametani|first4=Fuyuki|last5=Tsuchiya|first5=Ayako|last6=Matsuda|first6=Masayuki|last7=Takenaka|first7=Yoshiaki|last8=Hosh|first8=Yoshinobu|last9=Ikeda|first9=Shu-ichi|date=2008-06|title=AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report|url=https://pubmed.ncbi.nlm.nih.gov/18484339|journal=Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis|volume=15|issue=2|pages=125–128|doi=10.1080/13506120802006229|issn=1744-2818|pmid=18484339}}</ref> and heavy-and-light-chain (AH/AL) amyloidosis are two rare forms of monoclonal Ig-related amyloidosis<ref>{{Cite journal|last=Nasr|first=Samih H.|last2=Said|first2=Samar M.|last3=Valeri|first3=Anthony M.|last4=Sethi|first4=Sanjeev|last5=Fidler|first5=Mary E.|last6=Cornell|first6=Lynn D.|last7=Gertz|first7=Morie A.|last8=Dispenzieri|first8=Angela|last9=Buadi|first9=Francis K.|date=2013-03|title=The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis|url=https://pubmed.ncbi.nlm.nih.gov/23302715|journal=Kidney International|volume=83|issue=3|pages=463–470|doi=10.1038/ki.2012.414|issn=1523-1755|pmid=23302715}}</ref><ref>{{Cite journal|last=Chaulagain|first=Chakra P.|last2=Herlitz|first2=Leal C.|last3=Fu|first3=Julie|last4=Bilani|first4=Nadeem|last5=Lucitt|first5=Camerun|last6=Comenzo|first6=Raymond L.|date=2020-11|title=How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)|url=https://pubmed.ncbi.nlm.nih.gov/32703752|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=11|pages=e826–e831|doi=10.1016/j.clml.2020.06.017|issn=2152-2669|pmid=32703752}}</ref>
==WHO Classification Pages (Includes Links to Content)==
==WHO Classification Pages (Includes Links to Content)==
*[[Primary Amyloidosis]]
*[[HAEM5:Immunoglobulin-related (AL) amyloidosis]]
*[[Light Chain and Heavy Chain Deposition Disease]]
*[[HAEM5:Monoclonal immunoglobulin deposition disease]]
==Other Related Pages (Includes Links to Content)==
==Other Related Pages (Includes Links to Content)==
*[[Plasma Cell Neoplasms]]
*[[HAEM4:Plasma Cell Neoplasms]]
*[[Lymphoplasmacytic Lymphoma]]
*[[HAEM5:Lymphoplasmacytic lymphoma]]
==Additional Information==
==Additional Information==